President Trump on Monday unveiled his plan to dramatically overhaul the way in which the U.S. pays for medicine by decreasing what he calls “inflated” costs to these paid by different nations. Pharma traders didn’t appear to care.
The XBI, a intently tracked index of biotech shares, was up over 4% by noon, whereas shares of huge pharma corporations additionally rose.
Regardless of considerations {that a} so-called most-favored nation coverage might roil the drug trade if enacted, the market strikes recommend traders had already baked in expectations that Trump would announce the coverage and are skeptical that he can efficiently implement it, largely due to anticipated authorized challenges and political obstacles.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
